Home › Acidosis › NCT07424625

A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients

THAM VErsus Sodium BiCarbOnate In CaRdiac SuRgical PatiEnts, A PragmatiC, Comparative-effectiveness Prospective Trial

Who can join

Ages 21 and older · All sexes

* Inclusion criteria

  * Cardiothoracic surgery with use of cardiopulmonary bypass
  * Presence of metabolic acidosis (defined as a base excess of \<-5)
  * Minnesota Research Authorization
* Exclusion criteria

  * Non-cardiac surgery patients or cardiac surgery without cardiopulmonary bypass
  * Absence of metabolic acidosis (metabolic acidosis being defined as a base excess of \<-5)
  * Pregnant patients
  * Prisoners
  * Opt out of Minnesota Research Authorization

About the study

The purpose of this research is to determine if two commonly used medications to treat metabolic acidosis in the setting of cardiac surgery, sodium bicarbonate and THAM, are equivalent.

What is being tested

• Sodium bicarbonate (drug)
• Tris-hydroxymethyl Aminomethane (drug)

Sponsor: Mayo Clinic · Participants: 250 · Started: Sep 14, 2026

Contact the study team

• Nicole M. Lenort, RRT, LRT · Phone: 866-265-9263

Official record on ClinicalTrials.gov — NCT07424625

Locations in the U.S.

Conditions

• Acidosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.